摘要
目的 探讨苦参素 +山莨菪碱预防非小细胞肺癌患者化疗后骨髓毒性的机理。方法 晚期非小细胞肺癌 39例 ,随机分为A组 2 5例 ,为治疗组 ;B组 1 4例 ,为对照组。 2组均用吡柔比星(THP) +异环磷酰胺 (IFO) +卡铂 (CBP)方案与卡铂 +依托泊苷方案交替化疗 ,治疗组在化疗同时加用苦参素 +山莨菪碱。 3周期后评价疗效和不良反应。结果 A组有效率为 68.0 % ,B组有效率为 57.1 % ,2组间疗效无显著性差异 (P >0 .0 5) ;A组与B组Ⅲ～Ⅳ级骨髓毒性发生率分别为 2 8.0 %和 42 .9% ,2组间有显著性差异 (P <0 .0 5)。心脏毒性发生率A组为 1例 ,为 1 3 .6 % ,B组未发生。结论 苦参素 +山莨菪碱能有效预防非小细胞肺癌化疗后的白细胞和血小板降低 。
Objective To investigate the mechanism of kurarinone combined with anisodamine in preventing bone marrow toxicity after non small cell lung cancer chemotherapy.Methods 39 patients with non small cell lung cancer were divided into two groups, group A (n=25) was treatment group and group B (n=14) was control group. All the patients received the following chemotherapy protocol: THP +IFO+CBP and etopside+carboplatin were administered alternatively, on the basis of chemotherapy, the patients in treatment group were given kurarinone combined with anisodamine in addition. The therapeutic effect and side effects were evaluated after three chemotherapy circles.Results The effective rate was 68.0% in group A and 57.1% in group B, there was no significant difference between two groups (P>0.05); the incidence of marrow toxicity (grade Ⅲ-Ⅳ)was 28.0%(7/25) in group A and 42.9% (6/14) in group B, there was a significant difference between two groups (P<0.05).Conclusion Kurarinone combined with anisodamine can effectively prevent the leukocyte reduction of non small cell lung cancer patients after treated by chemotherapy, and can improve the patients’ life quality.
出处
《疑难病杂志》
CAS
2003年第2期76-78,共3页
Chinese Journal of Difficult and Complicated Cases
关键词
非小细胞肺癌
化疗
骨髓毒性
苦参素
山莨菪碱
预防
Carcinoma,non small cell lung
Kurarinone
Anisodamine
Chemotherapy
Bone marrow toxicity
